220 related articles for article (PubMed ID: 25807961)
21. [Anagrelide in the treatment of thrombocythemia essential (ET)].
Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
[TBL] [Abstract][Full Text] [Related]
22. Treatment of children with anagrelide for thrombocythemia.
Lackner H; Urban C; Beham-Schmid C; Benesch M; Kerbl R; Schwinger W
J Pediatr Hematol Oncol; 1998; 20(5):469-73. PubMed ID: 9787322
[TBL] [Abstract][Full Text] [Related]
23. Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.
Levraut M; Legros L; Drappier C; Béné MC; Queyrel V; Raynaud S; Martis N
J Thromb Thrombolysis; 2020 Nov; 50(4):995-1003. PubMed ID: 32266587
[TBL] [Abstract][Full Text] [Related]
24. Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia.
Buxhofer-Ausch V; Wolf D; Sormann S; Forjan E; Schimetta W; Gisslinger B; Heibl S; Krauth MT; Thiele J; Ruckser R; Gisslinger H
Eur J Haematol; 2021 Jan; 106(1):58-63. PubMed ID: 32909297
[TBL] [Abstract][Full Text] [Related]
25. Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.
Martin K
Curr Hematol Malig Rep; 2017 Oct; 12(5):389-396. PubMed ID: 28948496
[TBL] [Abstract][Full Text] [Related]
26. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group.
Am J Med; 1992 Jan; 92(1):69-76. PubMed ID: 1731512
[TBL] [Abstract][Full Text] [Related]
27. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
28. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
29. JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
Hexner EO
Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351
[TBL] [Abstract][Full Text] [Related]
30. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
[TBL] [Abstract][Full Text] [Related]
31. Anagrelide: a review of its use in the management of essential thrombocythaemia.
Wagstaff AJ; Keating GM
Drugs; 2006; 66(1):111-31. PubMed ID: 16398570
[TBL] [Abstract][Full Text] [Related]
32. Predictive factors of thrombosis for patients with essential thrombocythaemia: A single center study.
Prajs I; Kuliczkowski K
Adv Clin Exp Med; 2017; 26(1):115-121. PubMed ID: 28397442
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia.
Laguna MS; Kornblihtt LI; Marta RF; Michiels JJ; Molinas FC
Clin Appl Thromb Hemost; 2000 Jul; 6(3):157-61. PubMed ID: 10898276
[TBL] [Abstract][Full Text] [Related]
34. Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine.
Mishcheniuk OY; Kostukevich OM; Dmytrenko IV; Sholoyko VV; Prokopenko IM; Martina ZV; Pilipenko GV; Klymenko SV
Exp Oncol; 2013 Sep; 35(3):202-6. PubMed ID: 24084459
[TBL] [Abstract][Full Text] [Related]
35. Ph
Košťál M; Schwarz J; Ovesná P; Penka M; Dulíček P;
J Thromb Thrombolysis; 2021 Jan; 51(1):112-119. PubMed ID: 32578055
[TBL] [Abstract][Full Text] [Related]
36. Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia.
Michiels JJ
Clin Appl Thromb Hemost; 1999 Oct; 5(4):247-51. PubMed ID: 10726022
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.
Basquiera AL; Soria NW; Ryser R; Salguero M; Moiraghi B; Sackmann F; Sturich AG; Borello A; Berretta A; Bonafé M; Barral JM; Palazzo ED; García JJ
Hematology; 2009 Dec; 14(6):323-30. PubMed ID: 19941738
[TBL] [Abstract][Full Text] [Related]
38. Are patients with thrombophilia and previous venous thromboembolism at higher risk to arterial thrombosis?
Linnemann B; Schindewolf M; Zgouras D; Erbe M; Jarosch-Preusche M; Lindhoff-Last E
Thromb Res; 2008; 121(6):743-50. PubMed ID: 17804043
[TBL] [Abstract][Full Text] [Related]
39. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
Burkhard R; Adam H; Widmer L; Honegger HP
Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
[TBL] [Abstract][Full Text] [Related]
40. Frequency and characteristics of the
Ma Q
J Int Med Res; 2020 Dec; 48(12):300060520977729. PubMed ID: 33307939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
